Urokinase - Global Top Players Market Share and Ranking 2026- YH Research

日本语 | 中文

Home > Reports >Pharma & Healthcare > Urokinase - Global Top Players Market Share and Ranking 2026

Urokinase - Global Top Players Market Share and Ranking 2026

Publication Date: 2026-01-05
Report Id: 2815767
Industry: Pharma & Healthcare
Report Page: 104
Chart: 101

PDF Download

Publication Date: 2026-01-05
Report Id: 2815767
Industry: Pharma & Healthcare
Report Page: 104
Chart: 101

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Urokinase Definition
1.2 Global Urokinase Market Size and Forecast
1.2.1 By Consumption Value, Global Urokinase Market Size, 2021-2032
1.2.2 By Sales Quantity, Global Urokinase Market Size, 2021-2032
1.2.3 Global Urokinase Average Selling Price (ASP), 2021-2032
1.3 Japan Urokinase Market Size and Forecast
1.3.1 By Consumption Value, Japan Urokinase Market Size, 2021-2032
1.3.2 By Sales Quantity, Japan Urokinase Market Size, 2021-2032
1.3.3 Japan Urokinase Average Selling Price (ASP), 2021-2032
1.4 Share of Japan Urokinase Market with Respect to the Global Market
1.4.1 By Consumption Value, Japan Urokinase Market Share in Global, 2021-2032
1.4.2 By Sales Quantity, Japan Urokinase Market Share in Global, 2021-2032
1.4.3 Urokinase Market Size: Japan VS Global, 2021-2032
1.5 Urokinase Market Dynamics
1.5.1 Urokinase Market Drivers
1.5.2 Urokinase Market Restraints
1.5.3 Urokinase Industry Trends
1.5.4 Urokinase Industry Policy

2 Global Leading Manufacturers and Market Share
2.1 By Revenue of Urokinase, Global Market Share by Company, 2021-2026
2.2 By Sales Quantity of Urokinase, Global Market Share by Company, 2021-2026
2.3 Urokinase Average Selling Price (ASP) by Company, 2021-2026
2.4 Global Urokinase Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.5 Global Urokinase Concentration Ratio
2.6 Global Urokinase Mergers & Acquisitions, Expansion Plans
2.7 Global Urokinase Manufacturers Product Type
2.8 Head Office and Urokinase Production Site of Key Manufacturer
2.9 Urokinase Capacity of Major Manufacturers and Future Plan

3 Japan Leading Manufacturers and Market Share
3.1 By Revenue of Urokinase, Japan Market Share by Company, 2021-2026
3.2 By Sales Quantity of Urokinase, Japan Market Share by Company, 2021-2026
3.3 Japan Urokinase Urokinase Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Global Producing Regions
4.1 Global Urokinase Capacity, Output and Capacity Utilization, 2021-2032
4.2 Global Urokinase Capacity by Region
4.3 Global Urokinase Production & Forecast by Region, 2021 VS 2025 VS 2032
4.4 Global Urokinase Production by Region, 2021-2032
4.5 Global Urokinase Production Market Share & Forecast by Region, 2021-2032

5 Industry Chain Analysis
5.1 Urokinase Industry Chain
5.2 Urokinase Upstream Analysis
5.2.1 Urokinase Core Raw Materials
5.2.2 Main Manufacturers of Urokinase Core Raw Materials
5.3 Midstream Analysis
5.4 Downstream Analysis
5.5 Urokinase Production Mode
5.6 Urokinase Procurement Model
5.7 Urokinase Industry Sales Model and Sales Channels
5.7.1 Urokinase Sales Model
5.7.2 Urokinase Typical Distributors

6 Sights Urokinase Market Classification
6.1 Urokinase Classification by Type
6.1.1 Urokinase Powder
6.1.2 Urokinase Solution
6.1.3 by Type, Global Urokinase Consumption Value, 2021-2032
6.1.4 by Type, Global Urokinase Sales Quantity, 2021-2032
6.1.5 by Type, Global Urokinase Average Selling Price (ASP), 2021-2032
6.2 Urokinase Classification by Clinical Use
6.2.1 Pulmonary Embolism Thrombolysis
6.2.2 Deep Vein Thrombosis
6.2.3 Peripheral Arterial Occlusion Thrombolysis
6.2.4 Catheter / Cannula Occlusion Clearance
6.2.5 Others
6.2.6 by Clinical Use, Global Urokinase Consumption Value, 2021-2032
6.2.7 by Clinical Use, Global Urokinase Sales Quantity, 2021-2032
6.2.8 by Clinical Use, Global Urokinase Average Selling Price (ASP), 2021-2032
6.3 Urokinase Classification by Administration Approach
6.3.1 Systemic Infusion
6.3.2 Catheter-directed Thrombolysis (CDT)
6.3.3 Intracatheter Dwell / Lock Technique
6.3.4 by Administration Approach, Global Urokinase Consumption Value, 2021-2032
6.3.5 by Administration Approach, Global Urokinase Sales Quantity, 2021-2032
6.3.6 by Administration Approach, Global Urokinase Average Selling Price (ASP), 2021-2032
6.4 Urokinase Classification by Purity
6.4.1 Standard Clinical Grade
6.4.2 High-purity / Low-impurity Grade
6.4.3 Low Endotoxin / Low Bioburden Specifications
6.4.4 by Purity, Global Urokinase Consumption Value, 2021-2032
6.4.5 by Purity, Global Urokinase Sales Quantity, 2021-2032
6.4.6 by Purity, Global Urokinase Average Selling Price (ASP), 2021-2032

7 Sights by Application
7.1 Urokinase Segment by Application
7.1.1 Hospital
7.1.2 Clinic
7.1.3 Others
7.2 by Application, Global Urokinase Consumption Value & CAGR, 2021 VS 2025 VS 2032
7.3 by Application, Global Urokinase Consumption Value, 2021-2032
7.4 by Application, Global Urokinase Sales Quantity, 2021-2032
7.5 by Application, Global Urokinase Price, 2021-2032

8 Sales Sights by Region
8.1 By Region, Global Urokinase Consumption Value, 2021 VS 2025 VS 2032
8.2 By Region, Global Urokinase Consumption Value, 2021-2032
8.3 By Region, Global Urokinase Sales Quantity, 2021-2032
8.4 North America
8.4.1 North America Urokinase Market Size & Forecasts, 2021-2032
8.4.2 By Country, North America Urokinase Market Size Market Share
8.5 Europe
8.5.1 Europe Urokinase Market Size & Forecasts, 2021-2032
8.5.2 By Country, Europe Urokinase Market Size Market Share
8.6 Asia Pacific
8.6.1 Asia Pacific Urokinase Market Size & Forecasts, 2021-2032
8.6.2 By Country/Region, Asia Pacific Urokinase Market Size Market Share
8.7 South America
8.7.1 South America Urokinase Market Size & Forecasts, 2021-2032
8.7.2 By Country, South America Urokinase Market Size Market Share
8.8 Middle East & Africa

9 Sales Sights by Country Level
9.1 By Country, Global Urokinase Market Size & CAGR, 2021 VS 2025 VS 2032
9.2 By Country, Global Urokinase Consumption Value, 2021-2032
9.3 By Country, Global Urokinase Sales Quantity, 2021-2032
9.4 United States
9.4.1 United States Urokinase Market Size, 2021-2032
9.4.2 by Type, United States Urokinase Sales Quantity Market Share, 2025 VS 2032
9.4.3 by Application, United States Urokinase Sales Quantity Market Share, 2025 VS 2032
9.5 Europe
9.5.1 Europe Urokinase Market Size, 2021-2032
9.5.2 by Type, Europe Urokinase Sales Quantity Market Share, 2025 VS 2032
9.5.3 by Application, Europe Urokinase Sales Quantity Market Share, 2025 VS 2032
9.6 China
9.6.1 China Urokinase Market Size, 2021-2032
9.6.2 by Type, China Urokinase Sales Quantity Market Share, 2025 VS 2032
9.6.3 by Application, China Urokinase Sales Quantity Market Share, 2025 VS 2032
9.7 Japan
9.7.1 Japan Urokinase Market Size, 2021-2032
9.7.2 by Type, Japan Urokinase Sales Quantity Market Share, 2025 VS 2032
9.7.3 by Application, Japan Urokinase Sales Quantity Market Share, 2025 VS 2032
9.8 South Korea
9.8.1 South Korea Urokinase Market Size, 2021-2032
9.8.2 by Type, South Korea Urokinase Sales Quantity Market Share, 2025 VS 2032
9.8.3 by Application, South Korea Urokinase Sales Quantity Market Share, 2025 VS 2032
9.9 Southeast Asia
9.9.1 Southeast Asia Urokinase Market Size, 2021-2032
9.9.2 by Type, Southeast Asia Urokinase Sales Quantity Market Share, 2025 VS 2032
9.9.3 by Application, Southeast Asia Urokinase Sales Quantity Market Share, 2025 VS 2032
9.10 India
9.10.1 India Urokinase Market Size, 2021-2032
9.10.2 by Type, India Urokinase Sales Quantity Market Share, 2025 VS 2032
9.10.3 by Application, India Urokinase Sales Quantity Market Share, 2025 VS 2032
9.11 Middle East & Africa
9.11.1 Middle East & Africa Urokinase Market Size, 2021-2032
9.11.2 by Type, Middle East & Africa Urokinase Sales Quantity Market Share, 2025 VS 2032
9.11.3 by Application, Middle East & Africa Urokinase Sales Quantity Market Share, 2025 VS 2032

10 Manufacturers Profile
10.1 Syner-Med
10.1.1 Syner-Med Company Information, Head Office, Market Area, and Industry Position
10.1.2 Syner-Med Urokinase Models, Specifications, and Application
10.1.3 Syner-Med Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.1.4 Syner-Med Company Profile and Main Business
10.1.5 Syner-Med Recent Developments
10.2 Wanhua Biochem
10.2.1 Wanhua Biochem Company Information, Head Office, Market Area, and Industry Position
10.2.2 Wanhua Biochem Urokinase Models, Specifications, and Application
10.2.3 Wanhua Biochem Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.2.4 Wanhua Biochem Company Profile and Main Business
10.2.5 Wanhua Biochem Recent Developments
10.3 Jiangxi Haoran Bio-Pharma
10.3.1 Jiangxi Haoran Bio-Pharma Company Information, Head Office, Market Area, and Industry Position
10.3.2 Jiangxi Haoran Bio-Pharma Urokinase Models, Specifications, and Application
10.3.3 Jiangxi Haoran Bio-Pharma Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.3.4 Jiangxi Haoran Bio-Pharma Company Profile and Main Business
10.3.5 Jiangxi Haoran Bio-Pharma Recent Developments
10.4 Jiangsu Aidea Pharmaceutical
10.4.1 Jiangsu Aidea Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
10.4.2 Jiangsu Aidea Pharmaceutical Urokinase Models, Specifications, and Application
10.4.3 Jiangsu Aidea Pharmaceutical Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.4.4 Jiangsu Aidea Pharmaceutical Company Profile and Main Business
10.4.5 Jiangsu Aidea Pharmaceutical Recent Developments
10.5 Techpool
10.5.1 Techpool Company Information, Head Office, Market Area, and Industry Position
10.5.2 Techpool Urokinase Models, Specifications, and Application
10.5.3 Techpool Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.5.4 Techpool Company Profile and Main Business
10.5.5 Techpool Recent Developments
10.6 Microbic Biosystems
10.6.1 Microbic Biosystems Company Information, Head Office, Market Area, and Industry Position
10.6.2 Microbic Biosystems Urokinase Models, Specifications, and Application
10.6.3 Microbic Biosystems Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.6.4 Microbic Biosystems Company Profile and Main Business
10.6.5 Microbic Biosystems Recent Developments
10.7 LIVZON
10.7.1 LIVZON Company Information, Head Office, Market Area, and Industry Position
10.7.2 LIVZON Urokinase Models, Specifications, and Application
10.7.3 LIVZON Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.7.4 LIVZON Company Profile and Main Business
10.7.5 LIVZON Recent Developments
10.8 Wuhan Humanwell Pharma
10.8.1 Wuhan Humanwell Pharma Company Information, Head Office, Market Area, and Industry Position
10.8.2 Wuhan Humanwell Pharma Urokinase Models, Specifications, and Application
10.8.3 Wuhan Humanwell Pharma Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.8.4 Wuhan Humanwell Pharma Company Profile and Main Business
10.8.5 Wuhan Humanwell Pharma Recent Developments
10.9 Tianjin Biochem Pharma
10.9.1 Tianjin Biochem Pharma Company Information, Head Office, Market Area, and Industry Position
10.9.2 Tianjin Biochem Pharma Urokinase Models, Specifications, and Application
10.9.3 Tianjin Biochem Pharma Urokinase Sales Quantity, Revenue, Price and Gross Margin, 2021-2026
10.9.4 Tianjin Biochem Pharma Company Profile and Main Business
10.9.5 Tianjin Biochem Pharma Recent Developments

11 Conclusion

12 Appendix
12.1 Research Methodology
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Market Estimation Model
12.4 Disclaimer

According to YH Research, the global market for Urokinase should grow from US$ 87.28 million in 2025 to US$ 125 million by 2032, with a CAGR of 4.9% for the period of 2026-2032.

The strategic recalibration of 2025 U.S. tariff mechanisms is redefining global economic governance norms. This study deciphers the transmission mechanisms of tariff escalation pathways and global policy responses on corporate investment strategies, regional trade networks, and critical material supply architectures.

Urokinase

According to YH Research, the global market for Urokinase should grow from US$ 87.28 million in 2025 to US$ 125 million by 2032, with a CAGR of 4.9% for the period of 2026-2032.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

Urokinase is a clot-dissolving medicine. It is a natural enzyme (a protein) that activates the body’s own fibrinolytic system by converting plasminogen into plasmin, and plasmin then breaks down fibrin, which is the “mesh” that holds a blood clot together. This is why urokinase is called a thrombolytic or “clot-buster.” The market for urokinase mainly includes injectable products (usually a sterile powder that is dissolved before use) that are given in hospitals, either through a vein or through a catheter directly to the clot area, depending on the indication and local practice. The clinical risk that shapes this market is also simple: because the drug dissolves clots, it can also weaken normal clotting at injury sites, so bleeding is the key safety concern and a major reason urokinase is used in controlled hospital settings. 
A practical market definition should also include how urokinase is made, because that affects supply, regulatory burden, and cost. Urokinase products can differ by source. The U.S. Kinlytic label describes production from human neonatal kidney cells grown in tissue culture, and it explains extensive donor screening and virus testing/inactivation steps because it is derived from human source material. In contrast, some European product information describes urokinase that is extracted from human urine. These differences matter commercially: biologic sourcing and validation requirements make it harder for many manufacturers to enter, and they increase the importance of quality systems, change control, and reliable supply chains.

On the demand side, the most basic driver is that blood clots are common, and a subset of them are severe enough that rapid clot removal is lifesaving or limb-saving. The U.S. CDC says up to 900,000 people in the United States are affected by venous thromboembolism (VTE) each year, and VTE is linked to tens of thousands of deaths. Globally, cardiovascular diseases are still the leading cause of death, and they overlap with clot problems and high-risk hospital populations. These facts do not mean every clot patient needs urokinase. Most patients receive anticoagulants and supportive care, not thrombolytics. But they explain why hospitals continue to need a set of clot-management tools, including thrombolytic drugs, for the most urgent cases.

In 2025, global Urokinase production reached approximately 2736 BIU, with an average global market price of around US$ 30 per MIU. The global single-line production capacity ranges from 100 to 150 BIU per year. The industry's gross profit margin is approximately 25%-35%.

One of the clearest growth “pockets” for urokinase is catheter and access-device management. Modern medicine uses a large volume of central venous catheters for chemotherapy, nutrition, antibiotics, and dialysis. These devices can become blocked by thrombus or fibrin sheaths. In Europe, regulatory summaries describe urokinase use for clots in catheters or cannulae, which is essentially “catheter clearance.” Clinical literature on thrombolytic therapy for catheter occlusion discusses multiple agents and reports that thrombolytics can restore patency in a meaningful share of blocked catheters, with performance differences by drug and dosing strategy; this is a major reason hospitals keep thrombolytic protocols for catheter salvage. When catheter salvage works, it avoids line replacement, reduces procedure risk, and helps preserve access sites—especially important for dialysis and oncology patients. This clinical logic is also why companies publicly frame catheter clearance as an attractive commercial segment when they talk about bringing urokinase products back to market. 
A second demand segment is catheter-directed thrombolysis (CDT) for limb-threatening peripheral arterial occlusion or extensive venous thrombosis, where drug is infused locally through a catheter rather than given as a full systemic infusion. Product information for urokinase in Europe explicitly describes acute peripheral arterial occlusions and notes that catheter-directed local lysis is the preferred method of administration for that scenario. More recent reviews also describe CDT as an effective endovascular method for thrombotic peripheral artery occlusions, while emphasizing the need for careful monitoring because bleeding and other complications are real. This creates a steady, procedure-linked demand for urokinase (and competing thrombolytics) in hospitals that perform vascular interventions. The market driver here is not only disease incidence; it is the expansion of interventional capability, better imaging, and more hospitals building vascular teams that can do “minimally invasive” clot removal rather than open surgery in selected patients.

At the same time, a major market trend is that urokinase is not the only clot-buster, and in some very large indications it has been replaced by other approaches. In acute ischemic stroke, for example, many regions use alteplase or tenecteplase, and mechanical thrombectomy has grown for large-vessel occlusions. In myocardial infarction, primary PCI has replaced thrombolysis in many systems where rapid catheterization is available. These shifts matter because they move thrombolytic use toward more specialized niches. In catheter clearance specifically, alteplase has strong clinical adoption in many settings, and reviews discuss its clearance rates and how other agents compare. So, one trend in the urokinase market is “narrower but deeper”: fewer broad, mass-market indications, but ongoing need in hospital procedures and device-related clots where protocols and economics favor certain agents.

Global key players of urokinase include Syner-Med, LIVZON, Wanhua Biochem, etc. The top three players hold a share about 50%.

This report studies and analyses global Urokinase status and future trends, helps the client to determine the Urokinase market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Urokinase, and provides market size (in BIU & US$ million) and Year-over-Year growth, considering 2025 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Urokinase market size, history data 2021-2025, and forecast data 2026-2032, (US$ million) & (BIU)
(2) Global Urokinase sales, revenue, price by company, market share and industry ranking 2021-2026, (US$ million) & (BIU)
(3) Japan Urokinase sales, revenue, price by company, market share and industry ranking 2021-2026, (US$ million) & (BIU)
(4) Global Urokinase key consuming regions, consumption quantity, consumption value and demand structure
(5) Global Urokinase key producing regions, capacity, production, and year over year growth
(6) Urokinase industry chains, upstream, midstream and downstream
Market segment by players, this report covers
    Syner-Med
    Wanhua Biochem
    Jiangxi Haoran Bio-Pharma
    Jiangsu Aidea Pharmaceutical
    Techpool
    Microbic Biosystems
    LIVZON
    Wuhan Humanwell Pharma
    Tianjin Biochem Pharma

Market segment by Type, covers
    Urokinase Powder
    Urokinase Solution

Market segment by Clinical Use, covers
    Pulmonary Embolism Thrombolysis
    Deep Vein Thrombosis
    Peripheral Arterial Occlusion Thrombolysis
    Catheter / Cannula Occlusion Clearance
    Others

Market segment by Administration Approach, covers
    Systemic Infusion
    Catheter-directed Thrombolysis (CDT)
    Intracatheter Dwell / Lock Technique

Market segment by Purity, covers
    Standard Clinical Grade
    High-purity / Low-impurity Grade
    Low Endotoxin / Low Bioburden Specifications

Market segment by Application, can be divided into
    Hospital
    Clinic
    Others

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Urokinase product scope, global sales quantity, value and average price, Japan sales quantity, value and average price, development opportunities, challenges, trends, and policies
Chapter 2: Global Urokinase market share and ranking of major manufacturers, sales quantity, revenue, average price, 2021-2026
Chapter 3: Japan Urokinase market share and ranking of major manufacturers, sales quantity, revenue, average price, 2021-2026
Chapter 4: Global key producing regions of Urokinase, percent & CAGR, 2021-2032
Chapter 5: Urokinase industry chain, upstream, medium-stream, and downstream
Chapter 6: Segment by Type, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 7: Segment by Application, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 8: Segment in regional level, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 9: Segment in country level, sales quantity, average price, consumption value, percent & CAGR, 2021-2032
Chapter 10: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, sales quantity, average price, revenue, gross margin
Chapter 11: Conclusions